CNS Pharmaceuticals Ownership 2024 | Who Owns CNS Pharmaceuticals Now?

Overview RevenueFinancials Chart

Institutional Ownership

96.10%

Insider Ownership

0.70%

Retail Ownership

3.20%

Institutional Holders

16.00

CNS Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.11%	0.00%	124,000	-9,229	-6.93%	124,000,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	1.97%	-	26,800	26,800	100.00%	27,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.97%	-	13,196	13,196	100.00%	13,196,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.86%	0.00%	11,702	7,325	167.35%	12,000	Mar 31, 2023
VIRTU FINANCIAL LLC	0.82%	0.00%	11,119	11,119	100.00%	11,000	Mar 31, 2023
UBS GROUP AG	0.18%	-	2,457	1,244	102.56%	2,457,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	482	-	-	482,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	200,000	Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC	0.00%	-	53	19	55.88%	102,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	25	-	-	25,000	Mar 31, 2023
GRADIENT INVESTMENTS LLC	0.00%	-	7	-	-	7,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	1	1	100.00%	1,000	Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC	0.00%	-	1	-	-	1,000	Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-8	-100.00%	-	Mar 31, 2023

CNS Pharmaceuticals's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 9.11% of the company's total share outstanding, currently valued at $124.00M. The top 10 institutional shareholders own together 13.96% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.11%	0.00%	124,000	-9,229	-6.93%	124,000,000	Mar 31, 2023
VIRTU FINANCIAL LLC	0.82%	0.00%	11,119	11,119	100.00%	11,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.86%	0.00%	11,702	7,325	167.35%	12,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	1.97%	-	26,800	26,800	100.00%	27,000	Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC	0.00%	-	53	19	55.88%	102,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.97%	-	13,196	13,196	100.00%	13,196,000	Mar 31, 2023
UBS GROUP AG	0.18%	-	2,457	1,244	102.56%	2,457,000	Mar 31, 2023
GRADIENT INVESTMENTS LLC	0.00%	-	7	-	-	7,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	482	-	-	482,000	Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC	0.00%	-	1	-	-	1,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	200,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	25	-	-	25,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	1	1	100.00%	1,000	Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-8	-100.00%	-	Mar 31, 2023

The largest CNS Pharmaceuticals shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 124.00K shares of CNS Pharmaceuticals (CNSP), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	1.97%	-	26,800	26,800	100.00%	27,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.97%	-	13,196	13,196	100.00%	13,196,000	Mar 31, 2023
VIRTU FINANCIAL LLC	0.82%	0.00%	11,119	11,119	100.00%	11,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.86%	0.00%	11,702	7,325	167.35%	12,000	Mar 31, 2023
UBS GROUP AG	0.18%	-	2,457	1,244	102.56%	2,457,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	200,000	Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC	0.00%	-	53	19	55.88%	102,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	1	1	100.00%	1,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	25	-	-	25,000	Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC	0.00%	-	1	-	-	1,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	482	-	-	482,000	Mar 31, 2023
GRADIENT INVESTMENTS LLC	0.00%	-	7	-	-	7,000	Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-8	-100.00%	-	Mar 31, 2023
ARMISTICE CAPITAL, LLC	9.11%	0.00%	124,000	-9,229	-6.93%	124,000,000	Mar 31, 2023

As of Mar 31 2023, CNS Pharmaceuticals's largest institutional buyer is RENAISSANCE TECHNOLOGIES LLC. The company purchased 26.80K stocks of CNSP, valued at $27.00K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.11%	0.00%	124,000	-9,229	-6.93%	124,000,000	Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-8	-100.00%	-	Mar 31, 2023
GRADIENT INVESTMENTS LLC	0.00%	-	7	-	-	7,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	482	-	-	482,000	Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC	0.00%	-	1	-	-	1,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	25	-	-	25,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	1	1	100.00%	1,000	Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC	0.00%	-	53	19	55.88%	102,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	200,000	Mar 31, 2023
UBS GROUP AG	0.18%	-	2,457	1,244	102.56%	2,457,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.86%	0.00%	11,702	7,325	167.35%	12,000	Mar 31, 2023
VIRTU FINANCIAL LLC	0.82%	0.00%	11,119	11,119	100.00%	11,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.97%	-	13,196	13,196	100.00%	13,196,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	1.97%	-	26,800	26,800	100.00%	27,000	Mar 31, 2023

As of Mar 31 2023, CNS Pharmaceuticals's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -9.23K shares of CNSP, valued at $124.00M.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	1.97%	-	26,800	26,800	100.00%	27,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.97%	-	13,196	13,196	100.00%	13,196,000	Mar 31, 2023
VIRTU FINANCIAL LLC	0.82%	0.00%	11,119	11,119	100.00%	11,000	Mar 31, 2023
FMR LLC	0.01%	-	200	200	100.00%	200,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.00%	-	1	1	100.00%	1,000	Mar 31, 2023

CNS Pharmaceuticals's largest new institutional shareholder by number of shares is RENAISSANCE TECHNOLOGIES LLC, purchased 26.80K shares, valued at $27.00K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-8	-100.00%	-	Mar 31, 2023

CNS Pharmaceuticals's largest sold out institutional shareholder by shares sold is PNC FINANCIAL SERVICES GROUP, INC., sold -8.00 shares, valued at -, as of undefined.

CNS Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
VANGUARD INDEX FUNDS	0.00%	453,615	-	-	Dec 31, 2023
FIDELITY CONCORD STREET TRUST	0.00%	128,393	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	116,738	92,973	391.22%	Dec 31, 2023
EQ ADVISORS TRUST	0.00%	2,886	-	-	Dec 31, 2023
iSHARES TRUST	0.00%	38,201	-	-	Feb 29, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	3,118	-	-	Dec 31, 2023

CNS Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 453.62K shares, compromising 0.00% of its total assets.

CNS Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Sep, 22	16	-5.88%
30 Jun, 22	17	6.25%
31 Mar, 22	16	-11.11%
31 Dec, 21	18	5.88%
30 Sep, 21	17	-5.56%
30 Jun, 21	18	5.88%
31 Mar, 21	17	70.00%
31 Dec, 20	10	42.86%
30 Sep, 20	7	16.67%
30 Jun, 20	6	-33.33%
31 Mar, 20	9	50.00%
31 Dec, 19	6	-

As of 30 Sep 22, 16 institutions are holding CNS Pharmaceuticals's shares, representing a decrease of -5.88% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Sep, 22	1,282,389	7.15%
30 Jun, 22	1,196,819	-30.11%
31 Mar, 22	1,712,430	49.80%
31 Dec, 21	1,143,179	20.64%
30 Sep, 21	947,605	-28.57%
30 Jun, 21	1,326,664	4.15%
31 Mar, 21	1,273,790	83.12%
31 Dec, 20	695,601	567.42%
30 Sep, 20	104,223	11.52%
30 Jun, 20	93,458	-9.61%
31 Mar, 20	103,394	15.11%
31 Dec, 19	89,825	-

CNS Pharmaceuticals (CNSP) has 1.28M shares outstanding as of 30 Sep 22, up 7.15% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Sep, 22	96.10%	1.19%
30 Jun, 22	89.69%	0.51%
31 Mar, 22	132.38%	0.78%
31 Dec, 21	130.14%	1.21%
30 Sep, 21	103.59%	0.42%
30 Jun, 21	156.49%	0.65%
31 Mar, 21	154.93%	0.98%
31 Dec, 20	125.57%	34.90%
30 Sep, 20	18.97%	6.53%
30 Jun, 20	17.04%	4.79%
31 Mar, 20	18.86%	5.90%
31 Dec, 19	17.88%	-

As of 30 Sep 22, CNS Pharmaceuticals is held by 96.10% institutional shareholders, representing a 1.19% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Sep, 22	7	-22.22%
30 Jun, 22	9	-10.00%
31 Mar, 22	10	25.00%
31 Dec, 21	8	-11.11%
30 Sep, 21	9	-
30 Jun, 21	9	-30.77%
31 Mar, 21	13	225.00%
31 Dec, 20	4	33.33%
30 Sep, 20	3	200.00%
30 Jun, 20	1	-83.33%
31 Mar, 20	6	-
31 Dec, 19	6	-

7 institutional shareholders have increased their position in CNSP stock as of 30 Sep 22 compared to 9 in the previous quarter (a -22.22% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Sep, 22	1	-50.00%
30 Jun, 22	2	-50.00%
31 Mar, 22	4	33.33%
31 Dec, 21	3	-
30 Sep, 21	3	50.00%
30 Jun, 21	2	100.00%
31 Mar, 21	1	-
31 Dec, 20	1	-
30 Sep, 20	1	-
30 Jun, 20	1	-
31 Mar, 20	1	-
31 Dec, 19	-	-

1 institutional shareholders have reduced their position in CNSP stock as of 30 Sep 22 compared to 2 in the previous quarter (a -50.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Sep, 22	16	-5.88%	1,282,389	7.15%	96.10%	1.19%	7	-22.22%	1	-50.00%
30 Jun, 22	17	6.25%	1,196,819	-30.11%	89.69%	0.51%	9	-10.00%	2	-50.00%
31 Mar, 22	16	-11.11%	1,712,430	49.80%	132.38%	0.78%	10	25.00%	4	33.33%
31 Dec, 21	18	5.88%	1,143,179	20.64%	130.14%	1.21%	8	-11.11%	3	-
30 Sep, 21	17	-5.56%	947,605	-28.57%	103.59%	0.42%	9	-	3	50.00%
30 Jun, 21	18	5.88%	1,326,664	4.15%	156.49%	0.65%	9	-30.77%	2	100.00%
31 Mar, 21	17	70.00%	1,273,790	83.12%	154.93%	0.98%	13	225.00%	1	-
31 Dec, 20	10	42.86%	695,601	567.42%	125.57%	34.90%	4	33.33%	1	-
30 Sep, 20	7	16.67%	104,223	11.52%	18.97%	6.53%	3	200.00%	1	-
30 Jun, 20	6	-33.33%	93,458	-9.61%	17.04%	4.79%	1	-83.33%	1	-
31 Mar, 20	9	50.00%	103,394	15.11%	18.86%	5.90%	6	-	1	-
31 Dec, 19	6	-	89,825	-	17.88%	-	6	-	-	-

CNS Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Feb 06, 2024	Gumulka Jerzy	director	-	P-Purchase	Buy	33,333	$0.30	$10.00K	43,006

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Feb 06, 2024	Gumulka Jerzy	director	-	P-Purchase	Buy	33,333	$0.30	$10.00K	43,006

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Apr 10, 2024	Mahery Amy	director	-	A-Award	Buy	17,500	-	-	47,420
Apr 10, 2024	Mahery Amy	director	-	A-Award	Buy	17,500	$0.26	$4.53K	29,920
Apr 10, 2024	Keyes Jeffry R.	director	-	A-Award	Buy	17,500	-	-	80,428
Apr 10, 2024	Keyes Jeffry R.	director	-	A-Award	Buy	17,500	$0.26	$4.53K	62,928
Apr 10, 2024	Gumulka Jerzy	director	-	A-Award	Buy	17,500	-	-	147,594
Apr 10, 2024	Gumulka Jerzy	director	-	A-Award	Buy	17,500	$0.26	$4.53K	129,594
Apr 10, 2024	Evans Carl Anthony	director	-	A-Award	Buy	17,500	-	-	147,094
Apr 10, 2024	Evans Carl Anthony	director	-	A-Award	Buy	17,500	$0.26	$4.53K	129,594
Apr 10, 2024	Downs Christopher	officer	Chief Financial Officer	A-Award	Buy	40,000	-	-	241
Apr 10, 2024	Downs Christopher	officer	Chief Financial Officer	A-Award	Buy	40,000	$0.26	$10.34K	201
Apr 10, 2024	Cockroft Bettina M.	director	-	A-Award	Buy	17,500	-	-	53,074
Apr 10, 2024	Cockroft Bettina M.	director	-	A-Award	Buy	17,500	$0.26	$4.53K	35,574
Apr 10, 2024	Climaco John M	director, officer	Chief Executive Officer	A-Award	Buy	83,000	-	-	559,533
Apr 10, 2024	Climaco John M	director, officer	Chief Executive Officer	A-Award	Buy	83,000	$0.26	$21.46K	476,533
Apr 10, 2024	Charles Faith L.	director	-	A-Award	Buy	17,500	-	-	64,815
Apr 10, 2024	Charles Faith L.	director	-	A-Award	Buy	17,500	$0.26	$4.53K	47,315
Feb 06, 2024	Mahery Amy	director	-	A-Award	Buy	12,420	$0.25	$3.14K	12,420
Feb 06, 2024	Gumulka Jerzy	director	-	A-Award	Buy	33,333	$0.30	$10.00K	112,094
Feb 06, 2024	Gumulka Jerzy	director	-	A-Award	Buy	33,333	$0.30	$10.00K	78,761
Feb 06, 2024	Gumulka Jerzy	director	-	P-Purchase	Buy	33,333	$0.30	$10.00K	43,006

The last insider buy of CNSP was made by Gumulka Jerzy on Feb 06 2024, buying 33,333 shares at $0.30 per share (worth $10.00K).

CNS Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2023	2	-	-
Q2 2023	8	2	400.00%
Q1 2023	2	13	15.38%
Q4 2022	1	4	25.00%
Q2 2022	2	-	-
Q1 2022	4	-	-
Q4 2021	3	-	-
Q3 2021	4	-	-
Q1 2021	2	-	-
Q3 2020	1	-	-
Q2 2020	4	1	400.00%
Q4 2019	1	6	16.67%

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by CNS Pharmaceuticals's insiders, as of Q3 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2023	2	-	-
Q2 2023	4	-	-
Q1 2023	-	13	-
Q4 2022	-	4	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q4 2021	2	-	-
Q3 2021	-	-	-
Q1 2021	-	-	-
Q3 2020	1	-	-
Q2 2020	-	-	-
Q4 2019	-	-	-

As of Q3 2023, Insider owners conducted 2 open market buy trades and 0 open market sell trades of CNS Pharmaceuticals's stocks.

CNS Pharmaceuticals Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
CWBR	CohBar, Inc.
VECT	VectivBio Holding AG
ELEV	Elevation Oncology, Inc.
IMMX	Immix Biopharma, Inc.
OCEA	Ocean Biomedical, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
ENVB	Enveric Biosciences, Inc.
AVRO	AVROBIO, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.

CNSP Ownership FAQ

Who Owns CNS Pharmaceuticals?

CNS Pharmaceuticals is owned by institutional shareholders (96.10%), insiders (0.70%), and public (3.20%). The largest institutional shareholder of CNS Pharmaceuticals is ARMISTICE CAPITAL, LLC (9.11% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

Who are the major institutional shareholders of CNS Pharmaceuticals?

CNS Pharmaceuticals's major institutional shareholders are ARMISTICE CAPITAL, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, TOWER RESEARCH CAPITAL LLC (TRC), and VIRTU FINANCIAL LLC. The top five shareholders own together 13.72% of the company's share outstanding.

How many CNS Pharmaceuticals shareholders are there?

As of Sep 2022, there are 16 institutional shareholders of CNS Pharmaceuticals.

What percentage of CNS Pharmaceuticals is owned by ARMISTICE CAPITAL, LLC?

ARMISTICE CAPITAL, LLC owns 124K shares of CNS Pharmaceuticals, representing 9.11% of the company's total shares outstanding, valued at $124M (as of Mar 2023).

What percentage of CNS Pharmaceuticals is owned by RENAISSANCE TECHNOLOGIES LLC?

As of Mar 2023, RENAISSANCE TECHNOLOGIES LLC holds 26.8K shares of CNS Pharmaceuticals (CNSP), compromising 1.97% of the company, valued at $27K.

What percentage of CNS Pharmaceuticals is owned by CITADEL ADVISORS LLC?

CITADEL ADVISORS LLC is the third largest holder of CNS Pharmaceuticals. The company owns 13.2K of the company's shares outstanding (worth $13.2M).